Cannabis Investors: 3 Big Changes Coming Soon to Cronos Group’s (TSX:CRON)

Marijuana stock Cronos Group (TSX:CRON)(NASDAQ:CRON) is undergoing massive transformation. You need to know these coming changes.

| More on:
Female scientist in a hemp field checking plants and flowers, alternative herbal medicine concept

Image source: Getty Images

Cannabis firm Cronos Group (TSX:CRON)(NASDAQ:CRON) reported its third-quarter financial results on Wednesday this week and management has announced some significant changes to the business. Investors need be aware of the following fundamental changes to the company’s future operations and financial results presentations going forward.

Here’s what you need to know.

Big change in applicable accounting standards

First, the company will be changing its domicile to the United States and effective December 31, 2019, management will prepare and present financial statements under U.S. Generally Accepted Accounting Principles (U.S. GAAP) and moving away from the International Financial Reporting Standards (IFRS) to which Canadians are normally accustomed.

Although there has been serious efforts toward a convergence in the financial reporting standards from the two accounting standards-setting boards, FASB and IASB over the years, full convergence hasn’t been achieved yet.

There are still some differences and management at Cronos Group says “the extent of the impact of this change in accounting framework has not yet been quantified.”

The bottom line is that the company’s financial statements won’t be directly comparable to those of its Canadian peers anymore, and some analyst adjustments may be necessary to perfectly align the reports for any comparables analysis.

If the stock belongs to one’s investment portfolio, it may be time to review some important adjustment points between U.S. GAAP reported financials and their IFRS equivalents, especially as they apply to agricultural and manufacturing industries.

Hopefully the company will considerably highlight these changes and help guide Canadian investors.

Repurposing of a flagship production facility

Second is that the company intends to repurpose parts of its flagship production facility at Peace Naturals campus from cultivation activities toward research and development, production and manufacturing of derivative products as well as storage capabilities.

The impact of this decision is still being assessed, but management estimates a one-time charge of up to $15 million to the income statement heavily weighted into the coming fourth quarter report.

Investor beware: it’s possible that the company may post significant losses if there aren’t any derivative gains during the quarter.

Latest acquisition brings new corporate order

The acquisition of hemp outfit Redwood in September has led to executive management changes, a new product line launch and, more important, new segment reporting categories.

The company has created a new general manager position and is letting go of its chief operating officer and its chief commercial officer who will both soon be leaving the company.

Moreover, a new hemp brand, the PEACE+™ product line is being launched in the United States targeting wellness enthusiasts and the line will be tested in 1000 stores while management intends to use major shareholder Altria’s distribution network to access the U.S. convenience store retail channel to gain consumer insights.

The U.S. CBD market promises to significantly contribute to the company’s revenue going forward, and thanks to a strategic partner in Altria, the company is getting a much broader test market of 1000 stores vs. Ontario’s 25 stores at present.

In order to add weight to the U.S. market dominance idea, the new segment is big enough to prompt the company to report its financial results in United States dollars and report on only two segments, namely the U.S. and Rest of World segments. Canadian cannabis operations, which composed the company’s core business, may now fall into the “Rest of World” segment.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

More on Cannabis Stocks

edit Jars of marijuana
Cannabis Stocks

Are Cannabis Stocks a Good Buy in March 2023?

Cannabis stocks like Canopy Growth Corp (TSX:WEED) are still being talked about, but are they worth buying?

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Down 26% in a Month, Is Canopy a Buy Today?

Canopy Growth Corp (TSX:WEED) is down 26% in a month. Is it time to start bottom fishing?

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

What’s Next for Aurora Cannabis Stock?

Aurora Cannabis stock is down 99% from all-time highs. Is ACB stock a buy, sell, or hold in March 2023?

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Canopy Growth Stock: Undervalued Gem or Falling Knife?

Canopy Growth remains a high-risk bet, despite falling 95% from all-time highs. Let's see why you need to avoid WEED…

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

3 Things to Know About Canopy Growth Stock After Earnings

A new focus on profitability and sustainability might stop the cash burn at Canopy Growth, so the stock can see…

Read more »

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »